H Fred Martin, MD | |
56 S High Street, Arendtsville, PA 17303 | |
(717) 677-8626 | |
(717) 677-4783 |
Full Name | H Fred Martin |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 44 Years |
Location | 56 S High Street, Arendtsville, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1942260831 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | MD025270-E (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Wellspan Vna Home Care | York, PA | Home health agency |
Gettysburg Hospital | Gettysburg, PA | Hospital |
Chambersburg Hospital | Chambersburg, PA | Hospital |
York Hospital | York, PA | Hospital |
Mailing Address | Practice Location Address |
---|---|
H Fred Martin, MD Po Box 579, 56 S. High Street, Arendtsville, PA 17303-0579 Ph: (717) 677-8626 | H Fred Martin, MD 56 S High Street, Arendtsville, PA 17303 Ph: (717) 677-8626 |
News Archive
The benefits of fetal surgery to repair spina bifida, a procedure pioneered at Vanderbilt University Medical Center (VUMC) in 1997, continue through school age, a National Institutes of Health (NIH) study reports today in the journal Pediatrics.
A Johns Hopkins team that included a trauma surgeon renowned for his treatment of gunshot victims has found that exposing at-risk children and teenagers to grizzly videos and photos of these patients' wounds can significantly change the youths' beliefs about the value and consequences of aggression.
AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only $58 million has been committed.
The Stroke Team at the Medical University of South Carolina (MUSC) in Charleston, SC, including Aquilla Turk, DO, Associate Professor of Radiology, M. Imran Chaudry, MD, Assistant Professor of Radiology, and Raymond D. Turner IV, MD, Assistant Professor of Neurosurgery and Radiology, enrolled the first patient in the Stroke Treatment And Revascularization Therapy (START) trial.
Sumitomo Heavy Industries, Ltd. announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo. Proton therapy is a form of radiation therapy, which employs proton beams to kill cancer cells with better dose distribution in comparison with conventional x-rays. Currently 12 facilities are operational and several more are under construction in the United States, and the U.S. proton therapy market is expected to expand in the future.
› Verified 3 days ago